NASDAQ$PRTA
Prothena Corporation plc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Reported financial results and business highlights for the third quarter of 2024.
Prothena reported a net loss of $59.0 million for the third quarter of 2024, compared to a net income of $21.9 million for the same period in 2023. Total revenue for the third quarter of 2024 was $1.0 million, primarily from collaboration revenue from Bristol Myers Squibb.
- Net loss for the third quarter of 2024 was $59.0 million, compared to a net income of $21.9 million for the third quarter of 2023.
- Total revenue for the third quarter of 2024 was $1.0 million, primarily from collaboration revenue from Bristol Myers Squibb.
- Cash and restricted cash position at the end of the quarter was $520.1 million.
- Prothena expects multiple clinical readouts starting in mid-2025 and continuing throughout the year from the ongoing Phase 1 ASCENT clinical trials evaluating PRX012 for Alzheimer’s disease.
Headline financials
Revenue & EPS history
Prothena · Revenue · Quarterly
$970K
Revenue by segment
Prothena · $84.9M total across 1 segment · Q3 2023
- Collaboration Revenue$84.9M+5557.7%100.0%
Forward guidance
The Company continues to expect full year 2024 net cash used in operating and investing actives to be $148 to $160 million and expects to end the year with approximately $468 million (midpoint) in cash, cash equivalents and restricted cash. The estimated full year 2024 net cash used from operating and investing activities is primarily driven by an estimated net loss of $120 to $135 million, which includes an estimated $48 million of non-cash share-based compensation expense.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
+1.5%
Avg return
Earnings day
+0.4%
Avg return
5 days after
+0.2%
Avg return
30 days after
57%
30 / 53 earnings
Positive
+45.3%
Q4 2020
Best reaction
-12.0%
Q1 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.1% | -8.7% | -16.5% | |
| Q4 2025 | -0.2% | -1.7% | -3.1% | |
| Q3 2025 | +5.2% | +7.6% | +9.8% | |
| Q1 2025 | +5.2% | -3.0% | -23.8% | |
| Q4 2024 | +2.0% | -4.6% | -15.0% | |
| Q3 2024 | -4.7% | -22.5% | -23.6% | |
| Q2 2024 | +6.7% | +3.7% | +5.6% | |
| Q1 2024 | -6.5% | -12.0% | -10.2% | |
| Q4 2023 | +2.7% | +0.9% | -4.5% | |
| Q3 2023 | +2.4% | -0.7% | -4.9% | |
| Q2 2023 | -8.7% | -9.7% | -18.3% | |
| Q1 2023 | +17.2% | +13.0% | +2.9% | |
| Q4 2022 | +4.6% | +7.0% | -9.7% | |
| Q3 2022 | -8.8% | -6.6% | +8.6% | |
| Q2 2022 | -8.5% | -2.8% | -19.1% | |
| Q1 2022 | -4.7% | -13.7% | -12.0% | |
| Q4 2021 | -9.6% | -8.3% | +5.1% | |
| Q3 2021 | -0.7% | -4.8% | -21.5% | |
| Q2 2021 | +5.0% | +5.8% | +30.5% | |
| Q1 2021 | -6.6% | -1.8% | +90.3% | |
| Q4 2020 | +45.3% | +46.2% | +46.5% | |
| Q3 2020 | +20.9% | +7.3% | +1.5% | |
| Q2 2020 | +3.5% | +1.5% | +8.2% | |
| Q1 2020 | -7.9% | -0.8% | -11.7% | |
| Q4 2019 | -0.1% | +0.9% | -22.7% | |
| Q3 2019 | -3.1% | -3.0% | +32.7% | |
| Q2 2019 | +2.4% | -2.2% | -1.3% | |
| Q1 2019 | +2.7% | -1.9% | -16.2% | |
| Q4 2018 | +3.1% | +4.3% | +12.5% | |
| Q3 2018 | +0.6% | -4.1% | -9.8% | |
| Q2 2018 | +2.7% | +8.2% | +3.6% | |
| Q1 2018 | -2.4% | +13.1% | -1.2% | |
| Q4 2017 | +8.0% | +11.6% | +18.1% | |
| Q3 2017 | -9.2% | -8.6% | -34.4% | |
| Q2 2017 | -4.2% | -7.1% | -1.3% | |
| Q1 2017 | +11.2% | +12.2% | +3.2% | |
| Q4 2016 | +1.4% | +5.9% | +3.9% | |
| Q3 2016 | -5.6% | -8.3% | +14.3% | |
| Q2 2016 | +2.8% | +2.3% | -7.9% | |
| Q1 2016 | -12.0% | — | — | |
| Q4 2015 | +1.4% | — | — | |
| Q3 2015 | +10.9% | — | — | |
| Q2 2015 | -1.1% | — | — | |
| Q1 2015 | -8.5% | — | — | |
| Q4 2014 | -0.2% | — | — | |
| Q3 2014 | -6.0% | — | — | |
| Q2 2014 | +12.2% | — | — | |
| Q1 2014 | +1.0% | — | — | |
| Q4 2013 | +0.5% | — | — | |
| Q3 2013 | +4.7% | — | — | |
| Q2 2013 | -1.6% | — | — | |
| Q1 2013 | +11.9% | — | — | |
| Q4 2012 | +0.6% | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro